文献速递技术与安全

并非所有肿瘤都相同:在球体模型中,FLASH对不同肿瘤类型和氧合状态的疗效存在差异

Not all tumors are alike: varying efficacy of FLASH across tumor types and oxygenation status in spheroid models.
PubMed 文献 · Br J Radiol · 2026-01-01

该研究用球体肿瘤模型评估超高剂量率照射(UHDR)杀灭癌细胞的效果,共分析3230个球体。常氧下UHDR与常规剂量率在U87、FaDusmall和T47D中无显著差异,而低氧条件下UHDR所需剂量显著更高,FaDularge球体在常氧下也显示更高剂量修饰因子。结论提示UHDR的等效性因肿瘤类型和条件而异。

要点

  • 常氧下U87、FaDusmall和T47D球体的UHDR与常规剂量率疗效无显著差异。
  • 低氧条件下U87、FaDusmall和T47D球体UHDR的DMFSCD50分别为1.14、1.07和1.13。
  • 常氧下FaDularge球体UHDR的DMFSCD50为1.66。

核心结论

  • 使用长期随访的球体肿瘤模型证明,UHDR的疗效因癌症类型和条件而异;小尺寸球体呈现等效性,而低氧张力和球体尺寸增大会导致更高的剂量修饰因子。

研究设计与样本

  • 临床前研究,使用胶质母细胞瘤(U87)、下咽鳞状细胞癌(FaDusmall和FaDularge两种尺寸)和乳腺腺癌(T47D)细胞来源的球体,共分析3230个球体,采用电子束在常氧或1%低氧条件下以UHDR(>200 Gy/s)或常规剂量率(约0.1 Gy/s)照射,U87和FaDusmall还接受质子照射,通过成像监测长达100天以确定50%球体治愈所需剂量(SCD50)。

诊断标准与关键数值

  • 以SCD50(50%球体治愈所需剂量)为指标,计算UHDR在50%存活水平下的剂量修饰因子(DMFSCD50);常氧下U87 DMFSCD50=0.98(P=.47),FaDusmall DMFSCD50=1.01(P=.75),T47D DMFSCD50=1.04(P=.25);低氧下U87 DMFSCD50=1.14(P<.01),FaDusmall DMFSCD50=1.07(P=.02),T47D DMFSCD50=1.13(P<.01);常氧下FaDularge DMFSCD50=1.66(P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Ultra-high dose rate irradiation (UHDR) has been shown to spare normal tissue in various model systems. This study evaluates its potential to sterilize cancer cells using spheroid tumor models.

METHODS: Spheroids from glioblastoma (U87), hypopharyngeal squamous cell carcinoma (2 sizes, FaDusmall and FaDularge) and breast adenocarcinoma (T47D) cells were irradiated with electron beams using UHDR (>200 Gy/s) or conventional dose rate (CONV, ∼0.1 Gy/s) exposures under ambient or reduced oxygen (1%) conditions. U87 and FaDusmall were also irradiated with protons. Spheroids were monitored using imaging for up to 100 days to determine the dose required to cure 50% of spheroids (SCD50). These data were used to calculate dose-modifying factor estimates for UHDR at the 50% survival level (DMFSCD50).

RESULTS: A total of 3230 spheroids were analyzed. Under ambient oxygen tension, UHDR and CONV showed no significant differences in U87 (DMFSCD50 = 0.98, P = .47), FaDusmall (DMFSCD50 = 1.01, P = .75), and T47D (DMFSCD50 = 1.04, P = .25), regardless of electron or proton irradiation. Under reduced oxygen levels, significantly higher UHDR doses were required to sterilize the spheroids, with DMFSCD50 1.14 (U87, P < .01), 1.07 (FaDusmall, P = .02), and 1.13 (T47D, P < .01). FaDularge-spheroids irradiated under ambient oxygen showed a DMFSCD50 of 1.66 (P < .001).

CONCLUSION: Using spheroid tumor models with long follow-up, we demonstrate that efficacy of UHDR varies across cancer types and conditions. Whereas small spheroids exhibit iso-efficacy, both reduced oxygen tension and increased spheroid size lead to higher DMF.

ADVANCES IN KNOWLEDGE: This preclinical study suggests that tumor iso-efficacy with UHDR may not hold true for all cancer types and is associated with oxygen level.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Dela R, Lemos Da Silva L, Beyer S, et al. Not all tumors are alike: varying efficacy of FLASH across tumor types and oxygenation status in spheroid models. Br J Radiol. 2026. PMID: 40878442. doi:10.1093/bjr/tqaf219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。